生物活性
GF 109203X是一种有效的PKC抑制剂，抑制PKCα，PKCβI，PKCβII和PKCγ，IC50分别为20 nM，17 nM，16nM和20 nM，作用于PKC比作用于EGFR，PDGFR和胰岛素受体选择性高3000倍以上。GF 109203X was a competitive inhibitor with respect to ATP (Ki = 14 +/- 3 NM) and displayed high selectivity for PKC as compared to five different protein kinases. GF 109203X inhibited collagen- and alpha-thrombin-induced platelet aggregation as well as collagen-triggered ATP secretion. GF 109203X reversed the inhibition of epidermal growth factor binding induced by phorbol 12,13-dibutyrate and prevented [3H] thymidine incorporation into DNA, only when this was elicited by growth promoting agents which activate PKC. GF 109203X was thought as a new type of drug interacting with P-gp directly, but does not support the concept of a major contribution of PKC to a P-gp-associated MDR, at least using the particular cellular model systems and the selective, albeit general, PKC inhibitor GF 109203X.
化学数据
| 分子量 | 412.49 |
| 分子式 | C25H24N4O2 |
| CAS号 | 133052-90-1 |
| 纯度 | 100.0% |
| 溶解性（25°C） | DMSO 79 mg/mL |
| 储存和运输条件 | 2-8°C, protect from light
常温运输及临时存放 |
实验操作 来自于公开的文献，仅供相同实验参考（如实验材料、目的不同，请参考其他文献）
| 细胞实验 |
|---|
| 细胞系 | SNU-407 colon cancer cells |
| 方法 | Monitoring cell proliferation by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Seeding cells in 96-well plates and allowing to grow overnight. Serum-starving the cells for 18–24 hours and then treating with 1 mM carbachol for 48 hours in 100 μL serum-free RPMI 1640. Adding inhibitors 30 min prior to carbachol treatment. Following the treatment, applying 10 μL of MTT solution (5 mg/ml) to each well, and incubating the plates for 3 h at 37 °C. After removing the medium, the formazan crystals formed are solubilized in 100 μL DMSO. Using a microplate reader to measure the absorbance at 570 nm and subtract the background absorbance at 690 nm . Each assay is performed in triplicate.
|
| 浓度 | 1 μM |
| 处理时间 | 48 hours |
| 动物实验 |
|---|
| 动物模型 | Wistar rats |
| 配制 | 10% DMSO in saline |
| 剂量 | 10 μg |
| 给药处理 | i.pl |
不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）
| 小鼠 | 大鼠 | 兔 | 豚鼠 | 仓鼠 | 狗 |
| 重量 (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| 体表面积 (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km系数 | 3 | 6 | 12 | 8 | 5 | 20 |
| 动物 A (mg/kg) = 动物 B (mg/kg) × | 动物 B的Km系数 |
| 动物 A的Km系数 |
例如，依据体表面积折算法，将化合物用于小鼠的剂量20 mg/kg 换算成大鼠的剂量，需要将20 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到化合物用于大鼠的等效剂量为10 mg/kg。
储备液配制
以下数据基于产品分子量，对于特殊产品，请参照COA中的储备液配制条件和说明进行操作。
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.4243 mL | 12.1215 mL | 24.243 mL |
| 5 mM | 0.4849 mL | 2.4243 mL | 4.8486 mL |
| 10 mM | 0.2424 mL | 1.2122 mL | 2.4243 mL |
